Orysia Bezpalko

Orysia Bezpalko

Auto-generated profile, based on publicly available information

Orysia Bezpalko

Center for Healthcare Quality and Analytics

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2013 in Journal of Controlled Release
Verified
Journal Article
Closed access
SLShayanne A. Lajud
Shayanne A. Lajud
ZHZhao Han
Zhao Han
FCFang-Lu Chi
Fang-Lu Chi
RGRende Gu
Rende Gu
DNDanish A. Nagda
Danish A. Nagda
DLDaqing Li
Daqing Li

25 February 2014 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
JZJ Zheng
J Zheng
DND A Nagda
D A Nagda
SLS A Lajud
S A Lajud
SKS Kumar
S Kumar
AMA Mouchli
A Mouchli
DLD Li
D Li
In this study, we evaluate whether the use of biliverdin (BV), a natural non-toxic antioxidant product of haeme catabolism, can suppress head and neck squamous cell carcinoma (HNSCC) cell proliferation and improve the tumour survival both in vitro and in vivo. Furthermore, we investigate whether this therapeutic outcome relies on BV’s potent antioxidant effect on reactive oxygen species (ROS)-mediated signalling. Two well-characterised HNSCC cell lines and a mouse model with human HNSCC were used for this study. In vitro, the effect of BV on ROS was assayed. Subsequently, critical regulatory proteins involved in growth, antiapoptotic, and angiogenic pathways were investigated by western blot analysis. In addition, the antiproliferative effect of BV was also evaluated using the clonogenic assay. Moreover, tumour growth inhibition was assessed using a mouse model with HNSCC. Biliverdin treatment resulted in decreased ROS, leading to suppression of proliferation and angiogenesis pathways of HNSCC, significantly decreasing the expression and phosphorylation of oncogenic factors such as epidermal growth factor receptor (EGFR), phosphorylation of Akt, and expression of angiogenic marker and transcription factor, hypoxia-inducible factor1-α (HIF1-α). Furthermore, this downregulation of ROS by BV led to a significant suppression of tumour growth in vivo. Our study demonstrates the efficacy of a novel therapeutic approach using BV as an antitumour agent against HNSCC through its effect on EGFR/Akt and HIF1-α/angiogenesis signal transduction pathways. Our findings indicate that BV’s inhibitory effect on these tumorigenic pathways relies on its antioxidant effect, and may extend its therapeutic potential to other solid cancers.

20 July 2018 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Closed access
PDF file
HHHillary Hei
Hillary Hei
OBOrysia Bezpalko
Orysia Bezpalko
SSSarah A. Smathers
Sarah A. Smathers
SCSusan E. Coffin
Susan E. Coffin
JSJulia S. Sammons
Julia S. Sammons
Objective: To reduce the healthcare-associated viral infection (HAVI) rate to 0.70 infections or fewer per 1,000 patient days by developing and sustaining a comprehensive prevention bundle.Setting: A 546-bed quaternary-care children’s hospital situated in a large urban area.Patients: Inpatients with a confirmed HAVI were included. These HAVIs were identified through routine surveillance by infection preventionists and were confirmed using National Healthcare Safety Network definitions for upper respiratory infections (URIs), pneumonia, and gastroenteritis.Methods: Quality improvement (QI) methods and statistical process control (SPC) analyses were used in a retrospective observational analysis of HAVI data from July 2012 through June 2016.Results: In total, 436 HAVIs were identified during the QI initiative: 63% were URIs, 34% were gastrointestinal infections, and 2.5% were viral pneumonias. The most frequent pathogens were rhinovirus (n=171) and norovirus (n=83). Our SPC analysis of HAVI rate revealed a statistically significant reduction in March 2014 from a monthly average of 0.81 to 0.60 infections per 1,000 patient days. Among HAVIs with event reviews completed, 15% observed contact with a sick primary caregiver and 15% reported contact with a sick visitor. Patient outcomes identified included care escalation (37%), transfer to ICU (11%), and delayed discharge (19%).Conclusions: The iterative development, implementation, and refinement of targeted prevention practices was associated with a significant reduction in pediatric HAVI. These practices were ultimately formalized into a comprehensive prevention bundle and provide an important framework for both patient and systems-level interventions that can be applied year-round and across inpatient areas.

5 November 2019 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Closed access
PDF file
CWCharlotte Z. Woods-Hill
Charlotte Z. Woods-Hill
LSLakshmi Srinivasan
Lakshmi Srinivasan
ESEmily Schriver
Emily Schriver
THTanya Haj-Hassan
Tanya Haj-Hassan
OBOrysia Bezpalko
Orysia Bezpalko
JSJulia S. Sammons
Julia S. Sammons
Objective: Central-line–associated bloodstream infections (CLABSI) cause morbidity and mortality in critically ill children. We examined novel and/or modifiable risk factors for CLABSI to identify new potential targets for infection prevention strategies.Methods: This single-center retrospective matched case-control study of pediatric intensive care unit (PICU) patients was conducted in a 60-bed PICU from April 1, 2013, to December 31, 2017. Case patients were in the PICU, had a central venous catheter (CVC), and developed a CLABSI. Control patients were in the PICU for ≥2 days, had a CVC for ≥3 days, and did not develop a CLABSI. Cases and controls were matched 1:4 on age, number of complex chronic conditions, and hospital length of stay.Results: Overall, 72 CLABSIs were matched to 281 controls. Univariate analysis revealed 14 risk factors, and 4 remained significant in multivariable analysis: total number of central line accesses in the 3 days preceding CLABSI (80+ accesses: OR, 4.8;P= .01), acute behavioral health needs (OR, 3.2;P= .02), CVC duration >7 days (8–14 days: OR, 4.2;P= .01; 15–29 days: OR, 9.8;P< .01; 30–59 days: OR, 17.3;P< .01; 60–89 days: OR, 39.8;P< .01; 90+ days: OR, 4.9;P= .01), and hematologic/immunologic disease (OR, 1.5;P= .05).Conclusions: Novel risk factors for CLABSI in PICU patients include acute behavioral health needs and >80 CVC accesses in the 3 days before CLABSI. Interventions focused on these factors may reduce CLABSIs in this high-risk population.

14 December 2014 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
SLShayanne A. Lajud
Shayanne A. Lajud
DNDanish A. Nagda
Danish A. Nagda
TYTaku Yamashita
Taku Yamashita
JZJun Zheng
Jun Zheng
NTNobuaki Tanaka
Nobuaki Tanaka
DLDaqing Li
Daqing Li
Purpose: Poly(ADP-ribose) polymerases (PARP) and the Mre11, Rad50, and Nbs1 (MRN) complex are key regulators of DNA repair, and have been recently shown to independently regulate telomere length. Sensitivity of cancers to PARPi is largely dependent on the BRCAness of the cells. Unfortunately, the vast majority of cancers are BRCA-proficient. In this study, therefore, we investigated whether a targeted molecular “hit” on the MRN complex, which is upstream of BRCA, can effectively sensitize BRCA-proficient head and neck squamous cell carcinoma (HNSCC) to PARP inhibitor (PARPi). Experimental Design: Human HNSCC cell lines and a mouse model with HNSCC xenografts were used in this study. In vitro and in vivo studies were conducted to evaluate the effects and underlying mechanisms of dual molecular disruption of PARP and the MRN complex, using a pharmacologic inhibitor and a dominant-negative Nbs1 expression vector, respectively. Results: Our findings demonstrate that downregulation of the MRN complex disrupts homologous recombination, and, when combined with PARPi, leads to accumulation of lethal DNA double-strand breaks. Moreover, we show that PARPi and MRN complex disruption induces significantly shortening telomere length. Together, our results demonstrate that dual disruption of these pathways causes significant cell death in BRCA-proficient tumor cells both in vitro and in vivo. Conclusion: Our study, for the first time, elucidates a novel mechanism for MRN complex and PARP inhibition beyond DNA repair, demonstrating the feasibility of a dual disruption approach that extends the utility of PARPi to the treatment of BRCA-proficient cancers. Clin Cancer Res; 20(24); 6465–78. ©2014 AACR.

12 November 2016 in Clinical Pediatrics
Verified
Journal Article
Closed access
MJManuel E Jimenez
Manuel E Jimenez
NDNathalie E. DuRivage
Nathalie E. DuRivage
OBOrysia Bezpalko
Orysia Bezpalko
ASAndrew Suh
Andrew Suh
RWRoy Wade
Roy Wade
AFAlexander G. Fiks
Alexander G. Fiks
Many young children identified with developmental concerns in pediatric settings do not receive early intervention (EI). We assessed the impact of a video decision aid and text message reminder on knowledge and attitudes regarding developmental delay and EI as well as referral completion. We conducted a pilot randomized controlled trial in an urban setting and enrolled 64 parent-child dyads referred to EI. Compared with controls, participants who received the intervention demonstrated increased knowledge regarding developmental delay and EI as well as more favorable attitudes in certain topics. Although we did not find a significant difference between arms in EI intake and evaluation, we found a pattern suggestive of increased intake and evaluation among participants with low health literacy in the intervention arm. Additional study is needed to identify strategies that improve the EI referral process for families and to understand the potential targeted role for decision aids and text messages.